2023
Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in mice
Jackman R, Darst O, Gaillard B, Tran J, Tomayko M, Muench M. Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in mice. Frontiers In Immunology 2023, 14: 1281123. PMID: 38090570, PMCID: PMC10711281, DOI: 10.3389/fimmu.2023.1281123.Peer-Reviewed Original ResearchConceptsAblative chemotherapyAlloantibody responsesPlatelet transfusionsB cellsPotent immunological effectsT cell responsesImpact of chemotherapyTransitional B cellsAllogeneic platelet transfusionsRisk of alloimmunizationNon-specific activationSubsequent transfusionsAllogeneic plateletsLymphocyte depletionBlood transfusionImmune dysregulationPlatelet recipientsSerum levelsPatient populationImmunological effectsImmunological environmentTransfusionRejection of transplantsChemotherapyHealthy peopleTargeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal Of Dermatology 2023, 190: 138-138. PMID: 37947404, DOI: 10.1093/bjd/ljad342.Peer-Reviewed Original ResearchMicrofluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.Peer-Reviewed Original ResearchConceptsB cell depletion therapyAcute COVID infectionAnti-spike IgGHigh-risk patientsCoronavirus disease-19COVID-19 pathologyDepletion therapyVaccine protectionAntibody responseCOVID infectionHematologic malignanciesImmune protectionDisease-19Healthy donorsMultiple time pointsSerology assaysBlood samplesSoluble markersB cellsImmunization strategiesPatientsFunctional deficiencySerological analysisTime pointsClonotype diversityImmune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearance
2021
COVID‐19 outcomes in patients with autoimmune blistering disease
Hwang E, Tomayko M. COVID‐19 outcomes in patients with autoimmune blistering disease. British Journal Of Dermatology 2021, 185: 1048-1050. PMID: 34107059, PMCID: PMC8239772, DOI: 10.1111/bjd.20571.Peer-Reviewed Original Research
2019
A Niche for Plasma Cells: The Skin
Karaaslan S, Tomayko MM. A Niche for Plasma Cells: The Skin. Journal Of Investigative Dermatology 2019, 139: 2411-2414. PMID: 31753124, DOI: 10.1016/j.jid.2019.06.133.Peer-Reviewed Original ResearchB cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For ImmunoTherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.Peer-Reviewed Original ResearchConceptsPD-1 inhibitorsB cell contentB-cell depletionAnti-tumor activityB cellsMuMT miceCell depletionAnti-PD-1 inhibitorsAnti-PD-1 responseB-cell depleting drugsTumor-infiltrating B cellsImpaired B-cell functionT cell-dependent tumor rejectionPD-1 inhibitionMC38 colon cancerB cell functionAnti-tumor effectsB-cell malignanciesMurine cancer modelsCell contentOverall survivalTumor rejectionCD20 antibodyAutoimmune disordersTumor shrinkageWhat B cell memories are made of
Tomayko MM, Allman D. What B cell memories are made of. Current Opinion In Immunology 2019, 57: 58-64. PMID: 30861463, DOI: 10.1016/j.coi.2019.01.003.Peer-Reviewed Original ResearchConceptsMemory B cellsB cell memoryB cellsPlasma cellsCell memoryAntigen-specific B cell receptorProtective serum antibodiesB cell receptorHumoral immunityIgG antibodiesSerum antibodiesSecondary exposureCell receptorUltimate outcomeAntigenAntibodiesMolecular eventsSame cellular pathwaysCellsCellular pathwaysIgMPathwayImmunityReceptors
2018
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2018, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsDrug EruptionsExanthemaFemaleHumansIpilimumabLichenoid EruptionsMaleMiddle AgedNivolumabRetrospective StudiesSkin NeoplasmsStevens-Johnson SyndromeWithholding TreatmentConceptsInflammatory eruptionsCheckpoint inhibitorsTherapeutic responseImmune checkpoint inhibitor therapySingle tertiary care centerSingle-institution retrospective analysisYale-New Haven HospitalCheckpoint inhibitor therapyTertiary care centerMinority of patientsInpatient dermatology serviceDegree of severityMost rashesInhibitor therapyRetrospective studyTopical treatmentEarly recognitionMedical recordsCare centerInflammatory reactionRetrospective analysisDermatology servicesImmunotherapyMean latencyGrade 2Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenDrug EruptionsFemaleHumansLichenoid EruptionsMaleMiddle AgedNeoplasm ProteinsNeoplasmsNivolumabPemphigoid, BullousProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin Diseases, VesiculobullousTertiary Care CentersTreatment OutcomeConceptsPD-L1 therapyAnti-PD-1/PD-L1 therapyBullous disordersBullous eruptionPD-1/PD-L1 therapyCell death ligand-1 therapyAnti-programmed cell death 1Cancer therapyDeath ligand 1 therapySingle tertiary care centerLinear IgA bullous dermatosisYale-New Haven HospitalDistinct therapeutic challengesInterruption of immunotherapyPositive tumor responseSteroid-sparing agentTertiary care centerIgA bullous dermatosisCell death 1New Haven HospitalStable diseaseSystemic corticosteroidsSystemic steroidsMaintenance therapyL1 therapy
1998
B cell maturation and selection at the marrow-periphery interface
Cancro M, Allman D, Hayes C, Lentz V, Fields R, Sah A, Tomayko M. B cell maturation and selection at the marrow-periphery interface. Immunologic Research 1998, 17: 3-11. PMID: 9479562, DOI: 10.1007/bf02786425.Peer-Reviewed Original ResearchConceptsB cell differentiationCell differentiationB cell longevityNormal B cell differentiationRegulatory genesSelective eventsNatural mutationsExpression changesB cell maturationCell longevityCell maturationLate maturationDifferentiationMaturationBone marrowPoolB cellsGenesDeletionMutationsRecruitmentLongevityCellsCritical periodEvents
1996
Human neuroblastoma cell lines regain catecholamine fluorescence when xenografted into athymic (nude) mice
Tomayko M, Triche T, Reynolds C. Human neuroblastoma cell lines regain catecholamine fluorescence when xenografted into athymic (nude) mice. International Journal Of Developmental Neuroscience 1996, 14: 771-777. PMID: 8960984, DOI: 10.1016/s0736-5748(96)00050-0.Peer-Reviewed Original ResearchConceptsNeuroblastoma cell linesPrimitive neuroectodermal tumorHuman neuroblastoma cell lineCatecholamine fluorescenceDense core granulesCatecholamine productionXenograft tumorsAthymic miceCell linesGlyoxylic acid-induced catecholamine fluorescenceHistochemical evidenceCore granulesNude mice tumor tissuesUseful tumor markerHuman neuroblastoma cellsMouse tumor tissuesNeuroblastoma patientsNeuroectodermal tumorUrinary catecholaminesTumor markersCatecholamine synthesisCorresponding tumorsHuman neuronsTumor tissueTumors
1993
Human neuroblastoma cell lines that express N‐myc without gene amplification
Wada R, Seeger R, Brodeur G, Einhorn P, Rayner S, Tomayko M, Reynolds C. Human neuroblastoma cell lines that express N‐myc without gene amplification. Cancer 1993, 72: 3346-3354. PMID: 8242562, DOI: 10.1002/1097-0142(19931201)72:11<3346::aid-cncr2820721134>3.0.co;2-e.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmAntigens, SurfaceBiomarkers, TumorCatecholaminesCell DivisionChild, PreschoolGene AmplificationGene Expression Regulation, NeoplasticGenes, mycHumansKaryotypingMaleNeuritesNeuroblastomaProto-Oncogene Proteins c-mycTime FactorsTranscriptional ActivationTumor Cells, CulturedConceptsGenomic amplificationN-myc expressionCell linesN-mycNeuroblastoma cell linesUnique genetic rearrangementDouble minute chromosomesGene activationChromosome 2New cell lineGenetic rearrangementsChromosomal deletionsHuman neuroblastoma cell lineBone marrow metastasesStage IV neuroblastomaCell surface antigen expressionN-myc amplificationAggressive tumor behaviorGene amplificationSurface antigen expressionCytogenetic analysisN-myc RNAProgressive diseaseBiological basisMarrow metastases
1989
Determination of subcutaneous tumor size in athymic (nude) mice
Tomayko M, Reynolds C. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemotherapy And Pharmacology 1989, 24: 148-154. PMID: 2544306, DOI: 10.1007/bf00300234.Peer-Reviewed Original Research